메뉴 건너뛰기




Volumn 22, Issue 12, 2016, Pages 2908-2918

Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab

(24)  Martens, Alexander a   Wistuba Hamprecht, Kilian a   Foppen, Marnix Geukes b   Yuan, Jianda c   Postow, Michael A c,d   Wong, Phillip c   Romano, Emanuela e   Khammari, Amir f   Dreno, Brigitte f   Capone, Mariaelena g   Ascierto, Paolo A g   Di Giacomo, Anna Maria h   Maio, Michele h   Schilling, Bastian i,j   Sucker, Antje i,j   Schadendorf, Dirk i,j   Hassel, Jessica C j,k   Eigentler, Thomas K a   Martus, Peter l   Wolchok, Jedd D c,d   more..

f INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; LACTATE DEHYDROGENASE; TRANSCRIPTION FACTOR FOXP3; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; TUMOR MARKER;

EID: 84970047228     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2412     Document Type: Article
Times cited : (465)

References (50)
  • 1
    • 79959772576 scopus 로고    scopus 로고
    • Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
    • Robert C, Thomas L, Bondarenko I, O'Day S, M DJ, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
    • (2011) N Engl J Med , vol.364 , pp. 2517-2526
    • Robert, C.1    Thomas, L.2    Bondarenko, I.3    O'Day, S.4    M, D.J.5    Garbe, C.6
  • 3
    • 84928917822 scopus 로고    scopus 로고
    • Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma
    • Feb 9
    • Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015Feb 9; doi: 10.1200/JCO.2014.56.2736.
    • (2015) J Clin Oncol
    • Schadendorf, D.1    Hodi, F.S.2    Robert, C.3    Weber, J.S.4    Margolin, K.5    Hamid, O.6
  • 5
    • 84908354848 scopus 로고    scopus 로고
    • Antiprogrammed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial
    • Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Antiprogrammed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384:1109-17.
    • (2014) Lancet , vol.384 , pp. 1109-1117
    • Robert, C.1    Ribas, A.2    Wolchok, J.D.3    Hodi, F.S.4    Hamid, O.5    Kefford, R.6
  • 6
    • 84874830056 scopus 로고    scopus 로고
    • Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types
    • Ascierto PA, Kalos M, Schaer DA, Callahan MK, Wolchok JD. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res 2013;19:1009-20.
    • (2013) Clin Cancer Res , vol.19 , pp. 1009-1020
    • Ascierto, P.A.1    Kalos, M.2    Schaer, D.A.3    Callahan, M.K.4    Wolchok, J.D.5
  • 7
    • 24944459890 scopus 로고    scopus 로고
    • Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4
    • Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005;23:6043-53.
    • (2005) J Clin Oncol , vol.23 , pp. 6043-6053
    • Attia, P.1    Phan, G.Q.2    Maker, A.V.3    Robinson, M.R.4    Quezado, M.M.5    Yang, J.C.6
  • 8
    • 36748999428 scopus 로고    scopus 로고
    • Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade
    • Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007;13:6681-8.
    • (2007) Clin Cancer Res , vol.13 , pp. 6681-6688
    • Downey, S.G.1    Klapper, J.A.2    Smith, F.O.3    Yang, J.C.4    Sherry, R.M.5    Royal, R.E.6
  • 9
    • 84903818245 scopus 로고    scopus 로고
    • Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
    • Simeone E, Gentilcore G, Giannarelli D, Grimaldi AM, Caraco C, Curvietto M, et al. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother 2014; 63:675-83.
    • (2014) Cancer Immunol Immunother , vol.63 , pp. 675-683
    • Simeone, E.1    Gentilcore, G.2    Giannarelli, D.3    Grimaldi, A.M.4    Caraco, C.5    Curvietto, M.6
  • 10
    • 84911445469 scopus 로고    scopus 로고
    • Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes
    • Kitano S, Postow MA, Ziegler CG, Kuk D, Panageas KS, Cortez C, et al. Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes. Cancer Immunol Res 2014;2:812-21.
    • (2014) Cancer Immunol Res , vol.2 , pp. 812-821
    • Kitano, S.1    Postow, M.A.2    Ziegler, C.G.3    Kuk, D.4    Panageas, K.S.5    Cortez, C.6
  • 12
    • 84878432797 scopus 로고    scopus 로고
    • Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: An early increase in lymphocyte and eosinophil counts is associated with improved survival
    • Delyon J, Mateus C, Lefeuvre D, Lanoy E, Zitvogel L, Chaput N, et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol 2013;24:1697-703.
    • (2013) Ann Oncol , vol.24 , pp. 1697-1703
    • Delyon, J.1    Mateus, C.2    Lefeuvre, D.3    Lanoy, E.4    Zitvogel, L.5    Chaput, N.6
  • 13
    • 79953784382 scopus 로고    scopus 로고
    • Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)
    • Di Giacomo AM, Danielli R, Calabro L, Bertocci E, Nannicini C, Giannarelli D, et al. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol Immunother 2011;60:467-77.
    • (2011) Cancer Immunol Immunother , vol.60 , pp. 467-477
    • Di Giacomo, A.M.1    Danielli, R.2    Calabro, L.3    Bertocci, E.4    Nannicini, C.5    Giannarelli, D.6
  • 14
    • 84961290760 scopus 로고    scopus 로고
    • Anticancer immunotherapy by CTLA-4 blockade: Obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
    • Hannani D, Vetizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, et al. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res 2015;25:208-24.
    • (2015) Cell Res , vol.25 , pp. 208-224
    • Hannani, D.1    Vetizou, M.2    Enot, D.3    Rusakiewicz, S.4    Chaput, N.5    Klatzmann, D.6
  • 18
    • 84864008345 scopus 로고    scopus 로고
    • Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis
    • Weide B, Zelba H, Derhovanessian E, Pflugfelder A, Eigentler TK, Di Giacomo AM, et al. Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol 2012;30:1835-41.
    • (2012) J Clin Oncol , vol.30 , pp. 1835-1841
    • Weide, B.1    Zelba, H.2    Derhovanessian, E.3    Pflugfelder, A.4    Eigentler, T.K.5    Di Giacomo, A.M.6
  • 20
    • 84872841412 scopus 로고    scopus 로고
    • Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma
    • van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 2013;31:e439-42.
    • (2013) J Clin Oncol , vol.31 , pp. e439-e442
    • Van Rooij, N.1    Van Buuren, M.M.2    Philips, D.3    Velds, A.4    Toebes, M.5    Heemskerk, B.6
  • 23
    • 84875343764 scopus 로고    scopus 로고
    • Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma
    • Wilgenhof S, Du Four S, Vandenbroucke F, Everaert H, Salmon I, Lienard D, et al. Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma. J Immunother 2013;36:215-22.
    • (2013) J Immunother , vol.36 , pp. 215-222
    • Wilgenhof, S.1    Du Four, S.2    Vandenbroucke, F.3    Everaert, H.4    Salmon, I.5    Lienard, D.6
  • 24
    • 77950258677 scopus 로고    scopus 로고
    • Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: Lymphocyte count after 2 doses correlates with survival
    • Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010;116:1767-75.
    • (2010) Cancer , vol.116 , pp. 1767-1775
    • Ku, G.Y.1    Yuan, J.2    Page, D.B.3    Schroeder, S.E.4    Panageas, K.S.5    Carvajal, R.D.6
  • 25
    • 84939573580 scopus 로고    scopus 로고
    • Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab
    • Valpione S, Martinoli C, Fava P, Mocellin S, Campana LG, Quaglino P, et al. Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab. Eur J Cancer 2015;51:2086-94.
    • (2015) Eur J Cancer , vol.51 , pp. 2086-2094
    • Valpione, S.1    Martinoli, C.2    Fava, P.3    Mocellin, S.4    Campana, L.G.5    Quaglino, P.6
  • 26
    • 84930872031 scopus 로고    scopus 로고
    • Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
    • Ferrucci PF, Gandini S, Battaglia A, Alfieri S, Di Giacomo AM, Giannarelli D, et al. Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. Br J Cancer 2015;112:1904-10.
    • (2015) Br J Cancer , vol.112 , pp. 1904-1910
    • Ferrucci, P.F.1    Gandini, S.2    Battaglia, A.3    Alfieri, S.4    Di Giacomo, A.M.5    Giannarelli, D.6
  • 27
    • 84863672266 scopus 로고    scopus 로고
    • Biomarkers on melanoma patient T cells associated with ipilimumab treatment
    • Wang W, Yu D, Sarnaik AA, Yu B, Hall M, Morelli D, et al. Biomarkers on melanoma patient T cells associated with ipilimumab treatment. J Transl Med 2012;10:146.
    • (2012) J Transl Med , vol.10 , pp. 146
    • Wang, W.1    Yu, D.2    Sarnaik, A.A.3    Yu, B.4    Hall, M.5    Morelli, D.6
  • 29
    • 84896523495 scopus 로고    scopus 로고
    • Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: Comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells
    • Weide B, Martens A, Zelba H, Stutz C, Derhovanessian E, Di Giacomo AM, et al. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. Clin Cancer Res 2014;20:1601-9.
    • (2014) Clin Cancer Res , vol.20 , pp. 1601-1609
    • Weide, B.1    Martens, A.2    Zelba, H.3    Stutz, C.4    Derhovanessian, E.5    Di Giacomo, A.M.6
  • 31
    • 84954143592 scopus 로고    scopus 로고
    • Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab
    • Gebhardt C, Sevko A, Jiang H, Lichtenberger R, Reith M, Tarnanidis K, et al. Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab. Clin Cancer Res 2015;21:5453-9.
    • (2015) Clin Cancer Res , vol.21 , pp. 5453-5459
    • Gebhardt, C.1    Sevko, A.2    Jiang, H.3    Lichtenberger, R.4    Reith, M.5    Tarnanidis, K.6
  • 33
    • 8444244786 scopus 로고    scopus 로고
    • X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization
    • Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004;10:7252-9.
    • (2004) Clin Cancer Res , vol.10 , pp. 7252-7259
    • Camp, R.L.1    Dolled-Filhart, M.2    Rimm, D.L.3
  • 34
    • 73149092567 scopus 로고    scopus 로고
    • Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria
    • Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15: 7412-20.
    • (2009) Clin Cancer Res , vol.15 , pp. 7412-7420
    • Wolchok, J.D.1    Hoos, A.2    O'Day, S.3    Weber, J.S.4    Hamid, O.5    Lebbe, C.6
  • 35
    • 0030069896 scopus 로고    scopus 로고
    • Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors
    • Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87.
    • (1996) Stat Med , vol.15 , pp. 361-387
    • Harrell, F.E.1    Lee, K.L.2    Mark, D.B.3
  • 36
    • 84924267914 scopus 로고    scopus 로고
    • Pretreatment levels of absolute and relative eosinophil count to improve overall survival (OS) in patients with metastatic melanoma under treatment with ipilimumab, an anti CTLA-4 antibody
    • Schindler K, Harmankaya K, Postow MA, Frantal S, Bello D, Ariyan CE, et al. Pretreatment levels of absolute and relative eosinophil count to improve overall survival (OS) in patients with metastatic melanoma under treatment with ipilimumab, an anti CTLA-4 antibody. ASCO Meeting Abstracts 2013;31:9024.
    • (2013) ASCO Meeting Abstracts , vol.31 , pp. 9024
    • Schindler, K.1    Harmankaya, K.2    Postow, M.A.3    Frantal, S.4    Bello, D.5    Ariyan, C.E.6
  • 37
    • 25144493776 scopus 로고    scopus 로고
    • Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: A prognostic model
    • Schmidt H, Bastholt L, Geertsen P, Christensen IJ, Larsen S, Gehl J, et al. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer 2005;93:273-8.
    • (2005) Br J Cancer , vol.93 , pp. 273-278
    • Schmidt, H.1    Bastholt, L.2    Geertsen, P.3    Christensen, I.J.4    Larsen, S.5    Gehl, J.6
  • 38
    • 84930764131 scopus 로고    scopus 로고
    • The prognostic role of the preoperative absolute lymphocyte count and absolute monocyte count in patients with resected advanced melanoma
    • Rochet NM, Kottschade LA, Grotz TE, Porrata LF, Markovic SN. The prognostic role of the preoperative absolute lymphocyte count and absolute monocyte count in patients with resected advanced melanoma. Am J Clin Oncol 2015;38:252-8.
    • (2015) Am J Clin Oncol , vol.38 , pp. 252-258
    • Rochet, N.M.1    Kottschade, L.A.2    Grotz, T.E.3    Porrata, L.F.4    Markovic, S.N.5
  • 40
    • 77956473075 scopus 로고    scopus 로고
    • COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function
    • Veltman JD, Lambers ME, van Nimwegen M, Hendriks RW, Hoogsteden HC, Aerts JG, et al. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer 2010; 10:464:464.
    • (2010) BMC Cancer , vol.10 , pp. 464
    • Veltman, J.D.1    Lambers, M.E.2    Van Nimwegen, M.3    Hendriks, R.W.4    Hoogsteden, H.C.5    Aerts, J.G.6
  • 41
    • 33751531874 scopus 로고    scopus 로고
    • Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function
    • Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006;203:2691-702.
    • (2006) J Exp Med , vol.203 , pp. 2691-2702
    • Serafini, P.1    Meckel, K.2    Kelso, M.3    Noonan, K.4    Califano, J.5    Koch, W.6
  • 42
    • 84894639687 scopus 로고    scopus 로고
    • Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab
    • Tarhini AA, Edington H, Butterfield LH, Lin Y, Shuai Y, Tawbi H, et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One 2014;9:e87705.
    • (2014) PLoS One , vol.9
    • Tarhini, A.A.1    Edington, H.2    Butterfield, L.H.3    Lin, Y.4    Shuai, Y.5    Tawbi, H.6
  • 43
    • 33947689316 scopus 로고    scopus 로고
    • Regulation of carcinogenesis by IL-5 and CCL11: A potential role for eosinophils in tumor immune surveillance
    • Simson L, Ellyard JI, Dent LA, Matthaei KI, Rothenberg ME, Foster PS, et al. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J Immunol 2007;178:4222-9.
    • (2007) J Immunol , vol.178 , pp. 4222-4229
    • Simson, L.1    Ellyard, J.I.2    Dent, L.A.3    Matthaei, K.I.4    Rothenberg, M.E.5    Foster, P.S.6
  • 44
    • 84929965822 scopus 로고    scopus 로고
    • Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells
    • Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, Hammerling GJ. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol 2015;16:609-17.
    • (2015) Nat Immunol , vol.16 , pp. 609-617
    • Carretero, R.1    Sektioglu, I.M.2    Garbi, N.3    Salgado, O.C.4    Beckhove, P.5    Hammerling, G.J.6
  • 45
    • 61349100687 scopus 로고    scopus 로고
    • Myeloid-derived suppressor cells as regulators of the immune system
    • Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
    • (2009) Nat Rev Immunol , vol.9 , pp. 162-174
    • Gabrilovich, D.I.1    Nagaraj, S.2
  • 46
    • 84959510362 scopus 로고    scopus 로고
    • Prognostic score for patients with advanced melanoma treated with ipilimumab
    • Diem S, Kasenda B, Martin-Liberal J, Lee A, Chauhan D, Gore M, et al. Prognostic score for patients with advanced melanoma treated with ipilimumab. Eur J Cancer 2015;51:2785-91.
    • (2015) Eur J Cancer , vol.51 , pp. 2785-2791
    • Diem, S.1    Kasenda, B.2    Martin-Liberal, J.3    Lee, A.4    Chauhan, D.5    Gore, M.6
  • 47
    • 84861543054 scopus 로고    scopus 로고
    • Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and elaboration
    • Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med 2012;9:e1001216.
    • (2012) PLoS Med , vol.9
    • Altman, D.G.1    McShane, L.M.2    Sauerbrei, W.3    Taube, S.E.4
  • 49
    • 84901246811 scopus 로고    scopus 로고
    • Clinical experience with ipilimumab 3 mg/kg: Real-world efficacy and safety data from an expanded access programme cohort
    • Ascierto PA, Simeone E, Sileni VC, Pigozzo J, Maio M, Altomonte M, et al. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med 2014;12:116.
    • (2014) J Transl Med , vol.12 , pp. 116
    • Ascierto, P.A.1    Simeone, E.2    Sileni, V.C.3    Pigozzo, J.4    Maio, M.5    Altomonte, M.6
  • 50
    • 84929201793 scopus 로고    scopus 로고
    • Correlation of absolute and relative eosinophil counts with immunerelated adverse events in melanoma patients treated with ipilimumab
    • Schindler K, Harmankaya K, Kuk D, Mangana J, Michielin O, Hoeller C, et al. Correlation of absolute and relative eosinophil counts with immunerelated adverse events in melanoma patients treated with ipilimumab. ASCO Meeting Abstracts 2014;32:9096.
    • (2014) ASCO Meeting Abstracts , vol.32 , pp. 9096
    • Schindler, K.1    Harmankaya, K.2    Kuk, D.3    Mangana, J.4    Michielin, O.5    Hoeller, C.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.